PMID- 22186089
OWN - NLM
STAT- MEDLINE
DCOM- 20130408
LR  - 20220321
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Print)
IS  - 1087-2418 (Linking)
VI  - 17
IP  - 1
DP  - 2012 Feb
TI  - Immunologic monitoring in transplantation revisited.
PG  - 26-32
LID - 10.1097/MOT.0b013e32834ee402 [doi]
AB  - PURPOSE OF REVIEW: Tailoring immunosuppressive drugs to an individual's needs is 
      crucial to improve long-term outcomes of organ transplant patients. The purpose 
      of this review is to summarize the data on promising biomarkers able to detect 
      the risk of acute or chronic rejection and to discuss the potential issues for 
      their implementation in the clinic. RECENT FINDINGS: Multiple publications have 
      indicated that circulating antibodies targeting human leukocyte antigen (HLA) and 
      non-HLA antigens as well as donor-specific memory T cells are associated with 
      accelerated graft failure. Other studies published within the year show that 
      specific genomic and proteomic signatures obtained from urine, blood, and graft 
      tissue correlate with acute rejection in kidney and heart transplant patients. 
      SUMMARY: The development of reliable biomarkers is crucial for individualizing 
      therapy aimed at extending allograft survival and improving patient health. 
      Emerging data indicate that monitoring assays, likely used in panels, have the 
      potential to be diagnostic and possibly predictive of long-term outcome. In 
      addition to ongoing discovery efforts, progress in the field will require 
      multicenter validation, assay standardization, and commercialization so as to 
      efficiently deliver reliable testing strategies to the practicing clinician.
FAU - Cravedi, Paolo
AU  - Cravedi P
AD  - Renal Division, Department of Medicine, Mount Sinai School of Medicine, New York, 
      NY 10029, USA.
FAU - Heeger, Peter S
AU  - Heeger PS
LA  - eng
GR  - U01 AI063594-07S1/AI/NIAID NIH HHS/United States
GR  - R01 AI071185/AI/NIAID NIH HHS/United States
GR  - U01 AI063594/AI/NIAID NIH HHS/United States
GR  - U01 AI063594-08/AI/NIAID NIH HHS/United States
GR  - U01 AI063594-06/AI/NIAID NIH HHS/United States
GR  - U01 AI063594-07/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Chemokines)
RN  - 0 (HLA Antigens)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Biomarkers/blood/*metabolism/urine
MH  - Blood Proteins/immunology
MH  - Chemokines/urine
MH  - Chronic Disease
MH  - Graft Rejection/*immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - *Monitoring, Immunologic/methods
MH  - Organ Transplantation
MH  - RNA, Messenger/urine
MH  - Transcriptome/*immunology
MH  - Transplantation Tolerance/*immunology
MH  - Transplantation, Homologous/*immunology
PMC - PMC3285386
MID - NIHMS354920
EDAT- 2011/12/22 06:00
MHDA- 2013/04/09 06:00
PMCR- 2013/02/01
CRDT- 2011/12/22 06:00
PHST- 2011/12/22 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2013/04/09 06:00 [medline]
PHST- 2013/02/01 00:00 [pmc-release]
AID - 10.1097/MOT.0b013e32834ee402 [doi]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2012 Feb;17(1):26-32. doi: 
      10.1097/MOT.0b013e32834ee402.